Moderna Inc (MRNA)

$51.38 -0.99 (-1.89%)
Market Cap 20.69B
Revenue (ttm) 1.94B
Net Income (ttm) -2.82B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -145.16%
Debt to Equity Ratio 0.07
Volume 15,477,600
Avg Vol 11,759,818
Day's Range N/A - N/A
Shares Out 394.94M
Stochastic %K 10%
Beta 1.29
Analysts Hold
Price Target $42.65

Company Profile

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseas...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 714 6500
Address:
325 Binney Street, Cambridge, United States
AStrokeOfLuck
AStrokeOfLuck Mar. 21 at 7:12 PM
$PFE $MRNA $BNTX $SPY $NVAX
0 · Reply
wheresdannynow
wheresdannynow Mar. 20 at 7:22 PM
Animal health entering the mRNA phase. AI optimized vaccines + next gen delivery targeting dogs and cats is a real growth lane. $MRNA $BNTX $ZTS proving how valuable vaccine platforms can be. $BIOV advancing DPX + mRNA into companion animals = optionality.
0 · Reply
DragonAlgo
DragonAlgo Mar. 20 at 7:19 PM
🐉 $MRNA PUT — DragonAlgo® Signal Contract: MRNA PUT Expiry: 2026-03-20 | Strike: $62.00 | Type: PUT Option Plan (premium): Entry: $10.55 Stop: $7.60 TP1: $13.72 TP2: $17.94 TP3: $25.32 🔗 https://dragonalgo.com
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Mar. 20 at 6:30 PM
$NNVC : From Manufacturing to Clinical Execution NanoViricides has completed manufacturing of its NV-387 oral drug, a key step ahead of Phase 2 trials. With production in place, the company is preparing to enter clinical-stage testing, initially focused on Mpox. NV-387 is part of a broad-spectrum antiviral platform targeting multiple viruses, including coronaviruses, influenza, and RSV. Key implications: 🟰Removes a major manufacturing hurdle 🟰Enables progression into Phase 2 trials 🟰Supports a multi-indication platform strategy What to watch: 🟰Phase 2 initiation and data 🟰Clinical efficacy signals 🟰 Expansion into additional viral targets NNVC remains early-stage, but this milestone marks a clear step toward unlocking the platform’s broader potential. Communicated Disclaimer: https://tinyurl.com/TherealshortsqueezyNNVC Peers: $PFE $MRNA $BNTX $GILD
0 · Reply
IndyOne
IndyOne Mar. 20 at 6:07 PM
$MRNA It's alive !!! Nice pep. Could be a run. Let's go. news coming
0 · Reply
NasdaqKnight
NasdaqKnight Mar. 20 at 3:30 PM
$IBRX ABOUT TO SNAP BACK. Anktiva just landed on the Macau drug list—alongside $LLY $GILD $MRNA $BM. The 2-week bleed is over. 👉If this is helpful to you, tap @NasdaqKnight Anyone still short $IBRX might want to rethink that position. What happened ImmunityBio’s Anktiva is now officially on the Macau drug list. This isn’t “in review.” It’s done. And look who’s on the same list: $LLY, $GILD, $MRNA, $BM.X (Bristol-Myers level). Anktiva just walked into the blockbuster club. 📉 Two weeks in the red Price got hammered. Sentiment was garbage. That’s exactly when a real catalyst flips the script. Why this is violent Macau = gateway to Asia commercial access Anktiva is already FDA-approved in bladder cancer Being on this list = credibility stamp for Asia expansion What comes next Either a snap reversal today or a repricing over the next few sessions. Small-cap biotech + tier-1 pharma peers on the same regulatory list = prime setup for a squeeze. Don’t wait for a 50% move to ask if it’s too late.
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Mar. 20 at 3:21 PM
$NNVC: The Broad-Spectrum Antiviral Play No One’s Watching NanoViricides is developing broad spectrum antivirals that bind to and neutralize viruses directly. Their lead candidate (NV-387) targets COVID, flu, RSV, and Mpox, aiming for a platform, not a single drug. Recent milestones 🔸Completed Phase 1 safety trials 🔸Advanced manufacturing for Phase 2-ready drug 🔸Preparing for Phase 2 (Mpox focus) Catalysts 🔸Phase 2 launch + data 🔸Expansion into additional viral targets 🔸Regulatory updates / partnerships The antiviral market is already ~$60–70B, with long-term growth toward ~$90B+ NNVC is a microcap trying to capture that with a multi-virus approach Communicated Disclaimer: https://tinyurl.com/TherealshortsqueezyNNVC Peers: $PFE $MRNA $BNTX $GILD
0 · Reply
taxplanr
taxplanr Mar. 20 at 2:50 PM
$BNTX $MRNA $PFE AAP under fire everywhere https://thepostmillennial.com/myocarditis-found-only-in-covid-vaxxed-kids-study#google_vignette
0 · Reply
taxplanr
taxplanr Mar. 20 at 1:02 PM
Devastating childhood study shows only COVID vaccinated children suffered heart damage $BNTX $MRNA $PFE https://pmc.ncbi.nlm.nih.gov/articles/PMC12643559/
0 · Reply
Ventureville
Ventureville Mar. 20 at 12:42 PM
$MRNA and $MRK crushing it with that 5-year melanoma data - 49% lower recurrence risk using their mRNA vaccine + Keytruda. Whole mRNA immuno sector is heating up big time. Nice setup for innovative plays like $BVAXF $BIOV.CSE and their DPX platform.
0 · Reply
Latest News on MRNA
Moderna, Inc. (MRNA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Mar 10, 2026, 11:40 AM EDT - 11 days ago

Moderna, Inc. (MRNA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday?

Mar 9, 2026, 1:32 PM EDT - 12 days ago

What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday?

CAPR

FDA reversals leave investors worrying about the fates of other experimental drugs

Mar 6, 2026, 11:33 AM EST - 15 days ago

FDA reversals leave investors worrying about the fates of other experimental drugs

DNLI RGNX WVE

The Sun Will Shine On Moderna Again - Initiating With A Buy

Mar 4, 2026, 3:16 PM EST - 16 days ago

The Sun Will Shine On Moderna Again - Initiating With A Buy

Why Moderna's $950M Patent Bill Is A Small Price For Pipeline Freedom

Mar 4, 2026, 11:05 AM EST - 17 days ago

Why Moderna's $950M Patent Bill Is A Small Price For Pipeline Freedom

Moderna rises as up to $2.25 billion settlement for COVID vaccine patent dispute to remove overhang

Mar 4, 2026, 8:26 AM EST - 17 days ago

Moderna rises as up to $2.25 billion settlement for COVID vaccine patent dispute to remove overhang

Moderna's $950 Million Settlement Clears Legal Overhang, Stock Soars

Mar 4, 2026, 8:14 AM EST - 17 days ago

Moderna's $950 Million Settlement Clears Legal Overhang, Stock Soars

Moderna Stock Rallies. This Big Risk Just Got Eliminated.

Mar 4, 2026, 5:25 AM EST - 17 days ago

Moderna Stock Rallies. This Big Risk Just Got Eliminated.

Moderna's stock rallies more than 10% as deal over a patent dispute clears vaccine pipeline

Mar 3, 2026, 5:30 PM EST - 17 days ago

Moderna's stock rallies more than 10% as deal over a patent dispute clears vaccine pipeline

Moderna to Pay $950 Million to Settle Patent Cases From Arbutus, Genevant

Mar 3, 2026, 4:46 PM EST - 17 days ago

Moderna to Pay $950 Million to Settle Patent Cases From Arbutus, Genevant

ABUS

Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute

Mar 3, 2026, 4:26 PM EST - 17 days ago

Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute

ABUS ROIV

Moderna, Inc. (MRNA) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Mar 3, 2026, 4:22 PM EST - 17 days ago

Moderna, Inc. (MRNA) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna

Mar 3, 2026, 4:15 PM EST - 17 days ago

Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna

ABUS ROIV

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

Mar 3, 2026, 4:15 PM EST - 17 days ago

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

ABUS ROIV

Moderna Resolves Global Patent Litigation with Arbutus/Genevant

Mar 3, 2026, 4:15 PM EST - 17 days ago

Moderna Resolves Global Patent Litigation with Arbutus/Genevant

ABUS

Moderna's Covid-Flu Vaccine Recommended for Approval in EU

Feb 27, 2026, 7:23 AM EST - 22 days ago

Moderna's Covid-Flu Vaccine Recommended for Approval in EU

European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19

Feb 27, 2026, 7:00 AM EST - 22 days ago

European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19

Moderna gets EU regulator nod for combined COVID, flu vaccine

Feb 27, 2026, 6:09 AM EST - 22 days ago

Moderna gets EU regulator nod for combined COVID, flu vaccine

Moderna Stock: How Far Can The Flu Shot Fly?

Feb 24, 2026, 10:40 AM EST - 25 days ago

Moderna Stock: How Far Can The Flu Shot Fly?

US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost

Feb 23, 2026, 3:15 PM EST - 25 days ago

US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost

MRK PFE

BioNTech sues Moderna for patent infringement over COVID-19 shots

Feb 19, 2026, 1:25 PM EST - 4 weeks ago

BioNTech sues Moderna for patent infringement over COVID-19 shots

BNTX

Moderna to Present at Upcoming Conferences in March 2026

Feb 19, 2026, 7:00 AM EST - 4 weeks ago

Moderna to Present at Upcoming Conferences in March 2026

FDA Makes U-Turn Again On Moderna New Flu Vaccine Review, Stock Soars

Feb 18, 2026, 1:20 PM EST - 4 weeks ago

FDA Makes U-Turn Again On Moderna New Flu Vaccine Review, Stock Soars

FDA agrees to review Moderna's mRNA flu vaccine application in a reversal

Feb 18, 2026, 11:17 AM EST - 4 weeks ago

FDA agrees to review Moderna's mRNA flu vaccine application in a reversal

Moderna Shares Rally 6% After FDA Reverses Decision Not To Review Flu Vaccine

Feb 18, 2026, 11:00 AM EST - 4 weeks ago

Moderna Shares Rally 6% After FDA Reverses Decision Not To Review Flu Vaccine

Moderna got the FDA to change its mind and review its flu vaccine after some concessions

Feb 18, 2026, 10:22 AM EST - 4 weeks ago

Moderna got the FDA to change its mind and review its flu vaccine after some concessions

FDA reverses decision not to review Moderna's new flu vaccine

Feb 18, 2026, 9:35 AM EST - 4 weeks ago

FDA reverses decision not to review Moderna's new flu vaccine

Moderna Says FDA Will Review Its Flu Vaccine. The Stock Is Rising.

Feb 18, 2026, 9:27 AM EST - 4 weeks ago

Moderna Says FDA Will Review Its Flu Vaccine. The Stock Is Rising.

The FDA reversed course and agreed to begin a review of Moderna's seasonal flu shot

Feb 18, 2026, 9:12 AM EST - 4 weeks ago

The FDA reversed course and agreed to begin a review of Moderna's seasonal flu shot

Health Rounds: Moderna combo flu/COVID vaccine succeeds in mid-stage trial

Feb 18, 2026, 7:13 AM EST - 4 weeks ago

Health Rounds: Moderna combo flu/COVID vaccine succeeds in mid-stage trial

US FDA to initiate review of Moderna's influenza vaccine

Feb 18, 2026, 7:07 AM EST - 4 weeks ago

US FDA to initiate review of Moderna's influenza vaccine

Moderna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submission

Feb 18, 2026, 7:00 AM EST - 4 weeks ago

Moderna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submission

Moderna Receives European Commission Marketing Authorization for COVID-19 Vaccine mNEXSPIKE

Feb 17, 2026, 7:00 AM EST - 4 weeks ago

Moderna Receives European Commission Marketing Authorization for COVID-19 Vaccine mNEXSPIKE

Moderna, Inc. (MRNA) Price Forecast: Breakout Signals New Bull Trend

Feb 13, 2026, 4:53 PM EST - 5 weeks ago

Moderna, Inc. (MRNA) Price Forecast: Breakout Signals New Bull Trend

MRNA Starts 2026 Volatile: Examining Rally & Pullback, Outsized Options

Feb 13, 2026, 4:13 PM EST - 5 weeks ago

MRNA Starts 2026 Volatile: Examining Rally & Pullback, Outsized Options

Moderna, Inc. (MRNA) Q4 2025 Earnings Call Transcript

Feb 13, 2026, 12:47 PM EST - 5 weeks ago

Moderna, Inc. (MRNA) Q4 2025 Earnings Call Transcript

Moderna Promises Revenue Growth In 2026, Even As FDA Flu Vaccine Setback Looms

Feb 13, 2026, 10:59 AM EST - 5 weeks ago

Moderna Promises Revenue Growth In 2026, Even As FDA Flu Vaccine Setback Looms

Moderna Narrows Loss, Reiterates 10% Revenue Growth Target

Feb 13, 2026, 7:56 AM EST - 5 weeks ago

Moderna Narrows Loss, Reiterates 10% Revenue Growth Target

Moderna Reports a Narrower-Than-Expected Loss. The Stock Falls After Earnings.

Feb 13, 2026, 7:13 AM EST - 5 weeks ago

Moderna Reports a Narrower-Than-Expected Loss. The Stock Falls After Earnings.

Moderna beats fourth-quarter revenue estimates

Feb 13, 2026, 7:06 AM EST - 5 weeks ago

Moderna beats fourth-quarter revenue estimates

Moderna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates

Feb 13, 2026, 7:00 AM EST - 5 weeks ago

Moderna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates

Moderna Stock Sports Technical Support Ahead Of Earnings

Feb 12, 2026, 3:25 PM EST - 5 weeks ago

Moderna Stock Sports Technical Support Ahead Of Earnings

Why is the FDA refusing Moderna's application for a new mRNA flu vaccine?

Feb 12, 2026, 5:10 AM EST - 5 weeks ago

Why is the FDA refusing Moderna's application for a new mRNA flu vaccine?

The FDA's refusal to review Moderna's application to sell a new flu shot is part of a pattern of regulatory U-turns and overruling of FDA staff by Vinay Prasad, head of the agency's vaccine division

Feb 11, 2026, 9:00 PM EST - 5 weeks ago

The FDA's refusal to review Moderna's application to sell a new flu shot is part of a pattern of regulatory U-turns and overruling of FDA staff by Vinay Prasad, head of the agency's vaccine division

FDA blindsides Moderna with refusal to review flu vaccine application: ‘We're pretty confused'

Feb 11, 2026, 3:15 PM EST - 5 weeks ago

FDA blindsides Moderna with refusal to review flu vaccine application: ‘We're pretty confused'

The FDA Refuses To Review Moderna's Flu Vaccine

Feb 11, 2026, 12:17 PM EST - 5 weeks ago

The FDA Refuses To Review Moderna's Flu Vaccine

Moderna's work developing seasonal vaccines is ‘risky' under current FDA, analyst says

Feb 11, 2026, 10:44 AM EST - 5 weeks ago

Moderna's work developing seasonal vaccines is ‘risky' under current FDA, analyst says

Moderna Stock Sinks. The FDA Delivers a Blow to Its New Flu Vaccine.

Feb 11, 2026, 7:05 AM EST - 5 weeks ago

Moderna Stock Sinks. The FDA Delivers a Blow to Its New Flu Vaccine.

Wall Street Breakfast Podcast: Amazon Adds BETA To Cart

Feb 11, 2026, 6:24 AM EST - 5 weeks ago

Wall Street Breakfast Podcast: Amazon Adds BETA To Cart

AMZN BETA EL WMT

AStrokeOfLuck
AStrokeOfLuck Mar. 21 at 7:12 PM
$PFE $MRNA $BNTX $SPY $NVAX
0 · Reply
wheresdannynow
wheresdannynow Mar. 20 at 7:22 PM
Animal health entering the mRNA phase. AI optimized vaccines + next gen delivery targeting dogs and cats is a real growth lane. $MRNA $BNTX $ZTS proving how valuable vaccine platforms can be. $BIOV advancing DPX + mRNA into companion animals = optionality.
0 · Reply
DragonAlgo
DragonAlgo Mar. 20 at 7:19 PM
🐉 $MRNA PUT — DragonAlgo® Signal Contract: MRNA PUT Expiry: 2026-03-20 | Strike: $62.00 | Type: PUT Option Plan (premium): Entry: $10.55 Stop: $7.60 TP1: $13.72 TP2: $17.94 TP3: $25.32 🔗 https://dragonalgo.com
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Mar. 20 at 6:30 PM
$NNVC : From Manufacturing to Clinical Execution NanoViricides has completed manufacturing of its NV-387 oral drug, a key step ahead of Phase 2 trials. With production in place, the company is preparing to enter clinical-stage testing, initially focused on Mpox. NV-387 is part of a broad-spectrum antiviral platform targeting multiple viruses, including coronaviruses, influenza, and RSV. Key implications: 🟰Removes a major manufacturing hurdle 🟰Enables progression into Phase 2 trials 🟰Supports a multi-indication platform strategy What to watch: 🟰Phase 2 initiation and data 🟰Clinical efficacy signals 🟰 Expansion into additional viral targets NNVC remains early-stage, but this milestone marks a clear step toward unlocking the platform’s broader potential. Communicated Disclaimer: https://tinyurl.com/TherealshortsqueezyNNVC Peers: $PFE $MRNA $BNTX $GILD
0 · Reply
IndyOne
IndyOne Mar. 20 at 6:07 PM
$MRNA It's alive !!! Nice pep. Could be a run. Let's go. news coming
0 · Reply
NasdaqKnight
NasdaqKnight Mar. 20 at 3:30 PM
$IBRX ABOUT TO SNAP BACK. Anktiva just landed on the Macau drug list—alongside $LLY $GILD $MRNA $BM. The 2-week bleed is over. 👉If this is helpful to you, tap @NasdaqKnight Anyone still short $IBRX might want to rethink that position. What happened ImmunityBio’s Anktiva is now officially on the Macau drug list. This isn’t “in review.” It’s done. And look who’s on the same list: $LLY, $GILD, $MRNA, $BM.X (Bristol-Myers level). Anktiva just walked into the blockbuster club. 📉 Two weeks in the red Price got hammered. Sentiment was garbage. That’s exactly when a real catalyst flips the script. Why this is violent Macau = gateway to Asia commercial access Anktiva is already FDA-approved in bladder cancer Being on this list = credibility stamp for Asia expansion What comes next Either a snap reversal today or a repricing over the next few sessions. Small-cap biotech + tier-1 pharma peers on the same regulatory list = prime setup for a squeeze. Don’t wait for a 50% move to ask if it’s too late.
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Mar. 20 at 3:21 PM
$NNVC: The Broad-Spectrum Antiviral Play No One’s Watching NanoViricides is developing broad spectrum antivirals that bind to and neutralize viruses directly. Their lead candidate (NV-387) targets COVID, flu, RSV, and Mpox, aiming for a platform, not a single drug. Recent milestones 🔸Completed Phase 1 safety trials 🔸Advanced manufacturing for Phase 2-ready drug 🔸Preparing for Phase 2 (Mpox focus) Catalysts 🔸Phase 2 launch + data 🔸Expansion into additional viral targets 🔸Regulatory updates / partnerships The antiviral market is already ~$60–70B, with long-term growth toward ~$90B+ NNVC is a microcap trying to capture that with a multi-virus approach Communicated Disclaimer: https://tinyurl.com/TherealshortsqueezyNNVC Peers: $PFE $MRNA $BNTX $GILD
0 · Reply
taxplanr
taxplanr Mar. 20 at 2:50 PM
$BNTX $MRNA $PFE AAP under fire everywhere https://thepostmillennial.com/myocarditis-found-only-in-covid-vaxxed-kids-study#google_vignette
0 · Reply
taxplanr
taxplanr Mar. 20 at 1:02 PM
Devastating childhood study shows only COVID vaccinated children suffered heart damage $BNTX $MRNA $PFE https://pmc.ncbi.nlm.nih.gov/articles/PMC12643559/
0 · Reply
Ventureville
Ventureville Mar. 20 at 12:42 PM
$MRNA and $MRK crushing it with that 5-year melanoma data - 49% lower recurrence risk using their mRNA vaccine + Keytruda. Whole mRNA immuno sector is heating up big time. Nice setup for innovative plays like $BVAXF $BIOV.CSE and their DPX platform.
0 · Reply
Betterworld1
Betterworld1 Mar. 20 at 11:35 AM
$MRNA WSJ :Days after a federal judge said the Department of Health and Human Services' vaccine committee members were improperly appointed, the agency is now considering whether to find a new slate of members for the panel or appeal the court's ruling, panel members said. The future of the committee was thrown into question after one member of the panel on Thursday announced that the committee would be dismantled. Hours later he said his earlier conclusion was based on miscommunication. The panel is charged with making vaccine recommendations to the Centers for Disease Control and Prevention.
0 · Reply
TCLutz
TCLutz Mar. 20 at 10:24 AM
$AZTR <— 💪🫡 $SPY $MRNA $ULTA $DRMA
0 · Reply
TCLutz
TCLutz Mar. 20 at 10:22 AM
$AZTR is going to continue way up all day. The filing shows Stonepine Capital and Nantahala Capital as the SPA buyers. Those guys are much bigger than AZTR and much bigger than anyone thought the buyers would be… Investors like that aren’t buying to do a day trade flip of $31MIL. 💪🫡 $SPY $MRNA $ULTA $DRMA
0 · Reply
shooshmonk
shooshmonk Mar. 20 at 8:45 AM
$MRNA should be an easy 10x from here
0 · Reply
StocktwitsNews
StocktwitsNews Mar. 20 at 5:55 AM
IBRX Stock Set To Snap 2 Weeks In Red: Anktiva Joins Global Blockbusters On Macau Drug List $IBRX $LLY $GILD $MRNA $BMY https://stocktwits.com/news/equity/markets/ibrx-stock-snap-losing-streak-anktiva-macau-drug-list/cZ3XLBrRIhU
1 · Reply
TCLutz
TCLutz Mar. 20 at 4:49 AM
$AZTR 👀 FULL NARRATIVE SHIFT: BEFORE (pre-March 19): • Near delisting risk • Going concern warning • Low cash (~$2M) • Pure clinical biotech (slow + risky) 👉 Market view: “This might not survive” ⸻ AFTER (today): • ✔ Funded (at least short-term) • ✔ Institutional + insider backing • ✔ New cosmetic biotech angle (faster monetization) 👉 Market view: “This now has optionality + runway” $MRNA $SPY $ULTA $BTC.X
0 · Reply
DragonAlgo
DragonAlgo Mar. 20 at 1:25 AM
🐉 $MRNA CALL — DragonAlgo® Signal Contract: MRNA CALL Expiry: 2026-03-20 | Strike: $45.00 | Type: CALL Option Plan (premium): Entry: $7.45 Stop: $5.36 TP1: $9.69 TP2: $12.66 TP3: $17.88 🔗 https://dragonalgo.com
0 · Reply
TCLutz
TCLutz Mar. 20 at 12:13 AM
$AZTR popped today mainly on its new financing + narrative shift.🔥💀🔥 The company announced a $10.5M raise (up to ~$31M with warrants) backed by institutional investors and insiders. That removes immediate going-concern risk and extends runway. At the same time, AZTR introduced a new angle: 👉 Expanding into cosmetic/cosmeceutical biotech (faster path to revenue vs drugs) Combined with: • Ongoing ATR-04 clinical trial (MD Anderson site) • Mid-2026 data catalyst The move is being driven by: ✔ Survival risk reduced ✔ Fresh capital + institutional backing ✔ New commercialization pathway Bottom line: Runway extension + new narrative + speculative biotech momentum = spike $MRNA $JNJ $ULTA $SPY
0 · Reply
BobJohnBuoy666
BobJohnBuoy666 Mar. 19 at 4:50 PM
$MRNA shorting this garbage
0 · Reply
ChessGM
ChessGM Mar. 19 at 4:27 PM
$MRNA https://youtu.be/aL5D4XqRo-8
0 · Reply
IndyOne
IndyOne Mar. 19 at 2:54 PM
$MRNA A new virus, Human Metapneumovirus (hMPV), is surging in California causing a rise in respiratory illnesses. The virus particularly impacts young children, older adults and those with weakened immune systems. While hMPV gets headlines, the greatest risk and hospitalizations are coming from Influenza A (H3N2). Moderna’s new mCOMBRIAX vaccine just received a positive opinion (recommendation to approve) from CHMP. Expect green light for Europe and new sales soon. Follow the money. Did I mention that Moderna has an infectious disease platform? More news coming.
1 · Reply
Ventureville
Ventureville Mar. 19 at 2:10 PM
mRNA is expanding beyond humans. Veterinary vaccines for rabies, lepto, FIP signal how fast the platform is scaling into animal health, a multi billion runway. Names like $MRNA $BNTX $ARCT pushing the tech forward. $BIOV.CSE / $BVAXF riding the broader immunotherapy and platform wave as mRNA and next gen delivery gain traction. Science scales. Markets follow.
1 · Reply